You are here: Industry Insights > AstraZeneca

News List

AZ’s Forxiga wins EU approval for heart failure pharmatimes
November 06, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the EU for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).
EC approves AstraZeneca and Merck’s Lynparza for two cancer types pharmaceutical-technology
November 06, 2020
AstraZeneca and Merck’s (MSD) Lynparza (olaparib) has secured approval from the European Commission for prostate cancer and ovarian cancer treatments in the European Union (EU).
AstraZeneca to Sell Atacand, Atacand Plus Commercial Rights to Cheplapharm americanpharmaceuticalreview
November 06, 2020
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH.
MHRA starts rolling review of AZ’s coronavirus vaccine pharmatimes
November 06, 2020
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has started an accelerated or rolling review of AstraZeneca’s coronavirus vaccine candidate, the British pharma giant confirmed on Sunday.
Fusion Pharma, AstraZeneca Enter Radiopharmaceuticals Alliance contractpharma
November 04, 2020
Leverages Fusion's Targeted Alpha Therapies platform and radiopharmaceuticals expertise and AstraZeneca's portfolio of antibodies and cancer therapies.
UK regulator initiates rolling review of AstraZeneca’s vaccine for Covid-19 pharmaceutical-technology
November 04, 2020
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has initiated the accelerated rolling review of AstraZeneca’s potential vaccine to treat Covid-19.
Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination contractpharma
November 02, 2020
cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site.
UK MHRA commences accelerated review for AstraZeneca’s COVID-19 vaccine candidate expresspharma
November 02, 2020
In rolling reviews, regulators can see clinical data in real-time and have discussions with pharma companies on manufacturing processes and trials to accelerate the approval process.
Clinical trials to study AstraZeneca’s COVID-19 vaccine resume globally europeanpharmaceuticalreview
October 29, 2020
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
Enhertu bags US priority review for HER2 gastric cancer pharmatimes
October 29, 2020
AstraZeneca’s Enhertu has scored a priority review from the US Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic gastric cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page